STOCK TITAN

Intelligent Bio Solutions Inc. - INBS STOCK NEWS

Welcome to our dedicated page for Intelligent Bio Solutions news (Ticker: INBS), a resource for investors and traders seeking the latest updates and insights on Intelligent Bio Solutions stock.

Intelligent Bio Solutions Inc. (INBS) is a progressive life sciences company committed to enhancing health care through innovative non-invasive diagnostic tests. The company's primary focus lies in developing real-time monitoring solutions that aid patients and health practitioners in managing chronic diseases efficiently. Through its cutting-edge Biosensor Platform, Intelligent Bio Solutions Inc. is pioneering diagnostic tests that are urgently required to improve patient outcomes and streamline medical diagnostics.

One of the company's significant advancements is in the realm of portable drug abuse testing. Utilizing fingerprint sweat analysis, INBS offers a non-invasive, hygienic, and rapid drug screening solution. This technology is engineered to detect the recent use of substances such as opioids, cocaine, methamphetamines, benzodiazepines, and marijuana, making it an invaluable tool in both clinical and legal settings.

Intelligent Bio Solutions Inc. has demonstrated substantial growth and success, as evidenced by an impressive year-over-year unaudited revenue increase of 80% for the fiscal third quarter and 193% for the nine months ending March 31, 2024. The company also reported its highest quarterly cartridge sales since acquiring Intelligent Fingerprinting in 2022, highlighting the growing demand and effectiveness of its products.

For more information, visit: http://www.ibs.inc/.

Rhea-AI Summary

Intelligent Bio Solutions Inc. (Nasdaq: INBS) announced an underwritten public offering of its common stock and warrants to purchase common stock. The offering is subject to market conditions, and there is no guarantee regarding its completion or the terms. Ladenburg Thalmann & Co. Inc. is the sole bookrunning manager for the offering. This offering is made under a shelf registration statement filed with the SEC, effective since April 20, 2022. A preliminary prospectus supplement will be available on the SEC's website. The press release clarifies that it does not constitute an offer to sell or purchase securities in jurisdictions where such offers would be unlawful.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-42.66%
Tags
-
Rhea-AI Summary

Intelligent Bio Solutions Inc. (Nasdaq: INBS) announced it has regained compliance with Nasdaq Listing Rule 5450(a)(1) regarding the Minimum Bid Price Requirement. This follows a notification received on February 27, 2023, confirming compliance was re-established after maintaining a minimum bid price of $1.00 for at least 10 consecutive trading days, effective February 24, 2023. The Company had previously been notified on March 17, 2022, of non-compliance due to a failure to maintain the minimum bid price for 30 consecutive business days.

The matter is now considered closed by Nasdaq.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.79%
Tags
none
-
Rhea-AI Summary

Intelligent Bio Solutions Inc. (Nasdaq: INBS) announced the filing of a 513(g) submission with the FDA for its Intelligent Fingerprinting Drug Screening Cartridge. This submission aims to identify the most suitable regulatory pathway as part of the company’s U.S. expansion strategy. The cartridge detects four drugs from fingerprint sweat in under ten minutes, emphasizing a quick and non-invasive testing process.

CEO Harry Simeonidis highlighted that this development is crucial in combating drug abuse and enhancing workplace safety.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.31%
Tags
none
Rhea-AI Summary

Intelligent Bio Solutions reported robust financial results for the second quarter ended December 31, 2022, with total revenue and government support income exceeding 100% year-over-year. Government support income rose 52% to $269,625, mainly from qualifying expenditures for Milestone 7. The company completed Milestone 7, achieving a four-fold improvement in time-to-result for its biosensor platform. Cash and equivalents totaled $2.9 million, and net loss decreased to $0.42 million from $3.46 million in the prior year. Strategic partnerships were announced with companies like Boughey Distribution and Hozelock for implementing non-invasive drug testing solutions, indicating promising growth potential.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.16%
Tags
-
Rhea-AI Summary

Intelligent Bio Solutions Inc. (Nasdaq: INBS) announced a 1-for-20 reverse stock split effective February 9, 2023. This decision, approved by stockholders on February 8, aims to boost the stock price to comply with Nasdaq's listing requirements. Post-split, every 20 shares will convert into one share, and the adjusted stock will trade under a new CUSIP number starting February 10. The reverse split will not change stockholder equity percentages, except for rounding up any fractional shares. Intelligent Bio Solutions develops non-invasive diagnostic tests, primarily benefiting industries requiring drug testing.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-16.67%
Tags
none
-
Rhea-AI Summary

Intelligent Bio Solutions Inc. (Nasdaq: INBS) announced that Boughey Distribution, a top UK logistics provider, has opted for its non-invasive, rapid fingerprint drug testing to replace traditional urine tests. This technology allows Boughey to conduct in-house random screenings, enhancing convenience and hygiene. The testing system analyzes fingerprint sweat to detect recent drug use, yielding results in just 10 minutes. The implementation aims to bolster health and safety within Boughey’s operations, as emphasized by their HR Head, Mark Batch.

The switch underscores the growing preference for fingerprint-based testing among logistics firms.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
8.49%
Tags
none
Rhea-AI Summary

Intelligent Bio Solutions Inc. (Nasdaq: INBS) announced a partnership with Hozelock to implement a non-invasive fingerprint sweat-based drug testing system aimed at enhancing employee safety. This technology allows for rapid testing of recent drug use, including opioids and cannabis, enabling efficient HR management during seasonal staffing fluctuations. The system promotes a supportive drug policy endorsed by the Unite trade union, emphasizing dignity and privacy for employees. Results from tests can be obtained quickly, making it a convenient solution for safety-critical industries.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.67%
Tags
none
-
Rhea-AI Summary

Intelligent Bio Solutions Inc. (INBS) has achieved a significant breakthrough in its biosensor platform, marking a 4x improvement in time-to-result (TTR), reducing it from 120 seconds to just 30 seconds. This milestone was validated at the University of Newcastle, Australia, where the platform was developed for non-invasive saliva-based diagnostics.

The enhancements include a new device architecture and ink that improves performance and reduces manufacturing costs. Additionally, the platform's limit of glucose detection has improved from 0.90 mg/dl to an impressive 0.36 mg/dl, opening pathways for diagnostic tests for hormones and cancers.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
293.13%
Tags
none
-
Rhea-AI Summary

On December 22, 2022, Intelligent Bio Solutions (Nasdaq: INBS) announced the closure of a Regulation S private placement, raising expected gross proceeds of $220,585. The offering involved 176,462 shares of Series D Convertible Preferred Stock and 529,386 warrants, priced at $1.25 per unit, including one share of Preferred Stock convertible into three common shares and three warrants with an exercise price of $0.29. Proceeds will support general working capital needs. This transaction reflects the company's ongoing focus on developing non-invasive diagnostic testing solutions.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.62%
Tags
none
Rhea-AI Summary

Intelligent Bio Solutions Inc. (Nasdaq: INBS) has announced the cancellation of its FY21 Annual Meeting originally set for June 16, 2022, due to lack of quorum. Instead, the company plans to hold its FY22 Annual Meeting virtually on or about February 8, 2023. This change comes as the company continues to develop its innovative Biosensor Platform and aims to address regulatory requirements to introduce diagnostic tests for chronic diseases. Shareholders are advised to refer to the SEC's Current Report for further details.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.17%
Tags
none

FAQ

What is the current stock price of Intelligent Bio Solutions (INBS)?

The current stock price of Intelligent Bio Solutions (INBS) is $1.34 as of December 23, 2024.

What is the market cap of Intelligent Bio Solutions (INBS)?

The market cap of Intelligent Bio Solutions (INBS) is approximately 6.0M.

What does Intelligent Bio Solutions Inc. specialize in?

Intelligent Bio Solutions Inc. specializes in developing non-invasive, real-time monitoring and diagnostic tests for managing chronic diseases and portable drug abuse testing.

What is the Biosensor Platform?

The Biosensor Platform is a technology developed by INBS for creating real-time diagnostic tests to assist in managing chronic illnesses and other medical conditions.

How does INBS's drug abuse testing technology work?

INBS uses fingerprint sweat analysis to offer a non-invasive, hygienic, and quick method of screening for recent drug use, including opioids, cocaine, and more.

What recent financial achievements has Intelligent Bio Solutions Inc. reported?

The company reported an 80% increase in year-over-year unaudited revenue for the fiscal third quarter and a 193% increase for the nine months ending March 31, 2024.

When did INBS achieve its highest quarterly cartridge sales?

INBS reported its highest quarterly cartridge sales since 2022, following the acquisition of Intelligent Fingerprinting.

Who are the primary contacts for Intelligent Bio Solutions Inc.?

Company-related inquiries can be directed to info@ibs.inc. For media-related queries, contact Cheryl Billson at cheryl.billson@commacomms.com or Valter Pinto at INBS@kcsa.com.

Where can I find more information about the company?

For more information about Intelligent Bio Solutions Inc., visit their official website at http://www.ibs.inc/.

What chronic diseases does INBS focus on with its diagnostic tests?

INBS focuses on creating diagnostic tests that assist in the management of various chronic diseases, though specific conditions are not detailed.

What substances can INBS's drug screening test detect?

INBS's drug screening test can detect recent use of opioids, cocaine, methamphetamines, benzodiazepines, and marijuana.

How does the fingerprint sweat analysis benefit users?

The fingerprint sweat analysis is non-invasive, hygienic, and fast, providing a convenient and reliable method for drug abuse testing.

Intelligent Bio Solutions Inc.

Nasdaq:INBS

INBS Rankings

INBS Stock Data

5.97M
4.26M
3.02%
14.38%
8.69%
Medical Devices
Surgical & Medical Instruments & Apparatus
Link
United States of America
NEW YORK